116 related articles for article (PubMed ID: 4344265)
21. Inhibition of respiratory virus infection by locally applied interferon.
Merigan TC; Reed SE; Hall TS; Tyrrell DA
Lancet; 1973 Mar; 1(7803):563-7. PubMed ID: 4120640
[No Abstract] [Full Text] [Related]
22. Inhibition of rhinovirus replication in in organ culture by a potential antiviral drug.
DeLong DC; Reed SE
J Infect Dis; 1980 Jan; 141(1):87-91. PubMed ID: 6245149
[TBL] [Abstract][Full Text] [Related]
23. Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Syncytial Virus and Other Respiratory Viruses.
Ohol YM; Wang Z; Kemble G; Duke G
PLoS One; 2015; 10(12):e0144648. PubMed ID: 26659560
[TBL] [Abstract][Full Text] [Related]
24. Duration of protection of calves against rhinovirus challenge exposure by infectious bovine rhinotracheitis virus-induced interferon in nasal secretions.
MacLachlan NJ; Rosenquist BD
Am J Vet Res; 1982 Feb; 43(2):289-93. PubMed ID: 6178325
[TBL] [Abstract][Full Text] [Related]
25. Iota-Carrageenan is a potent inhibitor of rhinovirus infection.
Grassauer A; Weinmuellner R; Meier C; Pretsch A; Prieschl-Grassauer E; Unger H
Virol J; 2008 Sep; 5():107. PubMed ID: 18817582
[TBL] [Abstract][Full Text] [Related]
26. Clinical evaluation of prophylactic intranasal 1-phenyl-3-(4-phenyl-2-thiazolyl) guanidine (CL 88,277) medication against rhinovirus 44 challenge.
Togo Y; Durr FE; Laurenzana DA
Med Microbiol Immunol; 1977 May; 163(1):37-44. PubMed ID: 195190
[TBL] [Abstract][Full Text] [Related]
27. Lanosterol Synthase Regulates Human Rhinovirus Replication in Human Bronchial Epithelial Cells.
McCrae C; Dzgoev A; Ståhlman M; Horndahl J; Svärd R; Große A; Großkopf T; Skujat MA; Williams N; Schubert S; Echeverri C; Jackson C; Guedán A; Solari R; Vaarala O; Kraan M; Rådinger M
Am J Respir Cell Mol Biol; 2018 Dec; 59(6):713-722. PubMed ID: 30084659
[TBL] [Abstract][Full Text] [Related]
28. A novel benzonitrile analogue inhibits rhinovirus replication.
Lacroix C; Querol-Audí J; Roche M; Franco D; Froeyen M; Guerra P; Terme T; Vanelle P; Verdaguer N; Neyts J; Leyssen P
J Antimicrob Chemother; 2014 Oct; 69(10):2723-32. PubMed ID: 24948704
[TBL] [Abstract][Full Text] [Related]
29. Application of oral bioavailability surrogates in the design of orally active inhibitors of rhinovirus replication.
Stratford RE; Clay MP; Heinz BA; Kuhfeld MT; Osborne SJ; Phillips DL; Sweetana SA; Tebbe MJ; Vasudevan V; Zornes LL; Lindstrom TD
J Pharm Sci; 1999 Aug; 88(8):747-53. PubMed ID: 10430536
[TBL] [Abstract][Full Text] [Related]
30. Parenteral inactivated rhinovirus vaccine: minimal protective effect.
Douglas RG; Couch RB
Proc Soc Exp Biol Med; 1972 Mar; 139(3):899-902. PubMed ID: 4336899
[No Abstract] [Full Text] [Related]
31. Studies with a rhinovirus of bovine origin. 3. The pathogenesis and pathology of infection with strain RS 3x in calves.
Ide PR; Darbyshire JH
Arch Gesamte Virusforsch; 1972; 36(3):335-42. PubMed ID: 4336495
[No Abstract] [Full Text] [Related]
32. Inhibition of rhinovirus RNA synthesis in diploid cells by a substituted guanidine compound having a different mode of action from guanidine.
Koliais SI Dimmock NJ
J Gen Virol; 1974 Jun; 23(3):341-5. PubMed ID: 4365491
[No Abstract] [Full Text] [Related]
33. Antiviral activity of constituents of Tamus communis.
Aquino R; Conti C; De Simone F; Orsi N; Pizza C; Stein ML
J Chemother; 1991 Oct; 3(5):305-9. PubMed ID: 1667189
[TBL] [Abstract][Full Text] [Related]
34. Effect of bovine fibroblast interferon on rhinovirus infection in calves.
Rosenquist BD; Allen GK
Am J Vet Res; 1990 Jun; 51(6):870-3. PubMed ID: 1695067
[TBL] [Abstract][Full Text] [Related]
35. Failure of a 3-substituted triazinoindole in the prevention of experimental human rhinovirus infection.
Togo Y; Schwartz AR; Hornick RB
Chemotherapy; 1973; 18(1):17-26. PubMed ID: 4344209
[No Abstract] [Full Text] [Related]
36. Evaluation of an enzyme-linked immunosorbent assay that measures rhinovirus-specific antibodies in human sera and nasal secretions.
Barclay WS; Callow KA; Sergeant M; al-Nakib W
J Med Virol; 1988 Aug; 25(4):475-82. PubMed ID: 2844987
[TBL] [Abstract][Full Text] [Related]
37. Antiviral effect of hyperthermic treatment in rhinovirus infection.
Conti C; De Marco A; Mastromarino P; Tomao P; Santoro MG
Antimicrob Agents Chemother; 1999 Apr; 43(4):822-9. PubMed ID: 10103186
[TBL] [Abstract][Full Text] [Related]
38. Effect of induced interferon in experimental rhinovirus infections in volunteers.
Douglas RG; Betts RF
Infect Immun; 1974 Mar; 9(3):506-10. PubMed ID: 4361353
[TBL] [Abstract][Full Text] [Related]
39. Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication.
Da Costa L; Scheers E; Coluccia A; Casulli A; Roche M; Di Giorgio C; Neyts J; Terme T; Cirilli R; La Regina G; Silvestri R; Mirabelli C; Vanelle P
J Med Chem; 2018 Sep; 61(18):8402-8416. PubMed ID: 30153009
[TBL] [Abstract][Full Text] [Related]
40. Viral therapy: prospects for protease inhibitors.
Korant BD; Towatari T; Ivanoff L; Petteway S; Brzin J; Lenarcic B; Turk V
J Cell Biochem; 1986; 32(2):91-5. PubMed ID: 3023407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
